Abstract  Description  Claims  Drawing  Search report  Cited references 

US61793463   [0001] 
US6210892B   [0005]  [0006] 
US5627274A   [0006] 
US5916808A   [0006] 
US5976879A   [0006] 
US5665593A   [0006] 
US7807816B   [0017]  [0017] 
US5698685A   [0051]  [0097] 
US5217866A   [0051]  [0097] 
US5142047A   [0051]  [0097] 
US5034506A   [0051]  [0097] 
US5166315A   [0051]  [0097] 
US5521063A   [0051]  [0097] 
US5506337A   [0051]  [0097] 
US8076476B   [0051]  [0097] 
US8299206B   [0051]  [0097] 
US7943762B   [0051]  [0097] 
US2011038459W   [0051] 
WO2011150408A   [0051] 
US5185444A   [0097] 
US118298   [0109] 
US5149797A   [0122] 
US20100016215A1   [0129] 
WO2012150960A   [0129] 
WO9402595A   [0136] 
WO9610391A   [0142] 
WO9610390A   [0142] 
WO9610392A   [0142] 
US6692911B   [0143]  [0143] 
US7163695B   [0143]  [0143] 
US7070807B   [0143]  [0143] 
US3453259A   [0188] 
US3459731A   [0188] 
US3453257A   [0188] 
US3420788A   [0188] 
US3426011A   [0188] 
US5134127A   [0188] 
US4235871A   [0193] 
WO9614057A   [0193] 
US4737323A   [0195] 

Molecular Therapy Nucleic Acids   [0016] 
Journal of Cell Science   [0062] 
Int J Exp Pathol   [0062] 
Proc Natl Acad Sci USA   [0070] 
Muscle Nerve   [0074]  [0211] 
PLoS Curr.   [0074]  [0075] 
J Gen Med   [0095] 
Sci Tranl Med   [0135] 
Trends Cell Bio.   [0136] 
Delivery Strategies for Antisense Oligonucleotide Therapeutics   [0136] 
Cell Transplant   [0141] 
Prog Neuropsychopharmacol Biol Psychiatry   [0141] 
Chem. Rev.   [0142] 
Chem. Pharm. Bull.   [0142] 
Science   [0142] 
Biochim. Biophys. Acta   [0142] 
J. Biol. Chem.   [0142] 
Pharmaceutical Salts   [0144] 
Drug Development and Industrial Pharmacy   [0177] 
REV   [0177] 
J Pharm Sci   [0177] 
Plant Cell Tiss. Org. Cult.   [0186] 
Agnew. Chem. Int. Ed. Engl.   [0186] 
New RRC, Liposomes: A practical approach   [0193] 
Lasic DD, Liposomes from physics to applications   [0193] 
Science   [0200] 
Cancer Research   [0200] 
Cell   [0200] 
Science   [0200] 
Am. J. Med. Sci.   [0200] 
Science   [0200] 
Am. J. Resp. Cell Molec. Biol.   [0200] 
Proc. Natl. Acad. Sci. (USA)   [0200] 
J. Biol. Chem.   [0200] 
Science   [0200] 
Am. J. Med. Sci.   [0200] 
Clinical Research   [0200] 
Science   [0200] 
Population frequencies of inherited neuromuscular diseases - a world survey   [0225] 
Evidence-based path to newborn screening for Duchenne muscular dystrophy   [0225] 
Profiles of neuromuscular diseases. Duchenne muscular dystrophy   [0225] 
Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management   [0225] 
Quality of life, physical disability and respiratory impairment in Duchenne muscular dystrophy   [0225] 
Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy   [0225] 
Glucocorticoid corticosteroids for Duchenne muscular dystrophy   [0225] 
Local dystrophin restoration with antisense oligonucleotide PRO051   [0225] 
Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study   [0225] 
Systemic administration of PRO051 in Duchenne's muscular dystrophy   [0225] 
Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study   [0225] 
Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations   [0225] 
Dystrophin and mutations: one gene, several proteins, multiple phenotypes   [0225] 
The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. I. Natural history   [0225] 
Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle   [0225] 
Dystrophin immunity revealed by gene therapy in Duchenne muscular dystrophy   [0225] 
Use of epitope libraries to identify exon-specific monoclonal antibodies for characterization of altered dystrophins in muscular dystrophy   [0225] 
Immunohistological intensity measurements as a tool to assess sarcolemma-associated protein expression   [0225] 
The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy   [0225] 
Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study   [0225] 
The 6-minute walk test in Duchenne/Becker muscular dystrophy: longitudinal observations   [0225] 
Therapeutics in Duchenne muscular dystrophy   [0225] 
Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy   [0225] 
X-chromosome methylation in manifesting and healthy carriers of dystrophinopathies: concordance of activation ratios among first degree female relatives and skewed inactivation as cause of the affected phenotypes   [0225] 
The Effects of Low Levels of Dystrophin on Mouse Muscle Function and Pathology   [0225] 
Clinical investigation in Duchenne dystrophy: 2. Determination of the ''power'' of therapeutic trials based on the natural history   [0225] 
Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for Duchenne muscular dystrophy   [0225] 
Restoring dystrophin expression in Duchenne muscular dystrophy muscle: Progress in exon skipping and stop codon read through   [0225] 
Early corticosteroid treatment in 4 Duchenne muscular dystrophy patients: 14-year follow-up   [0225] 
Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse   [0225] 
Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs   [0225] 
Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense   [0225]